SEC Form 4 · accession 0001614740-26-000011
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Peetz
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 5:12 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001759425
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2026 | M | 20,000 | $2.936 | A | 214,309 | D | |
| Common StockF2 | Jul 6, 2026 | S | 12,134 | $121.65 | D | 202,175 | D | |
| Common StockF3 | Jul 6, 2026 | S | 4,181 | $122.34 | D | 197,994 | D | |
| Common StockF4 | Jul 6, 2026 | S | 1,975 | $123.74 | D | 196,019 | D | |
| Common StockF5 | Jul 6, 2026 | S | 1,710 | $124.79 | D | 194,309 | D | |
| Common Stock | holding | — | — | — | 187,500 | I | By The Peetz Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $2.936 | Jul 6, 2026 | M | 20,000 | D | — | Mar 11, 2029 | Common Stock | 20,000 | 108,487 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
- F2The weighted average sale price for the transaction reported was $121.65, and the range of prices were between $121.11 and $122.105. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3The weighted average sale price for the transaction reported was $122.34, and the range of prices were between $122.13 and $123.1125. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4The weighted average sale price for the transaction reported was $123.74, and the range of prices were between $123.24 and $124.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5The weighted average sale price for the transaction reported was $124.79, and the range of prices were between $124.27 and $124.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F6The stock option is fully vested.